Follow
Spero Cataland
Spero Cataland
Verified email at osumc.edu
Title
Cited by
Cited by
Year
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
M Scully, SR Cataland, F Peyvandi, P Coppo, P Knöbl, ...
New England Journal of Medicine 380 (4), 335-346, 2019
7502019
Caplacizumab for acquired thrombotic thrombocytopenic purpura
F Peyvandi, M Scully, JA Kremer Hovinga, S Cataland, P Knöbl, H Wu, ...
New England Journal of Medicine 374 (6), 511-522, 2016
5952016
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
M Scully, S Cataland, P Coppo, J De La Rubia, KD Friedman, JK Hovinga, ...
Journal of thrombosis and haemostasis 15 (2), 312-322, 2017
4162017
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
G Marcucci, JC Byrd, G Dai, MI Klisovic, PJ Kourlas, DC Young, ...
Blood, The Journal of the American Society of Hematology 101 (2), 425-432, 2003
3152003
Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial
F Fakhouri, M Hourmant, JM Campistol, SR Cataland, M Espinosa, ...
American journal of kidney diseases 68 (1), 84-93, 2016
2982016
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
XL Zheng, SK Vesely, SR Cataland, P Coppo, B Geldziler, A Iorio, ...
Journal of Thrombosis and Haemostasis 18 (10), 2496-2502, 2020
2642020
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura
XL Zheng, SK Vesely, SR Cataland, P Coppo, B Geldziler, A Iorio, ...
Journal of Thrombosis and Haemostasis 18 (10), 2486-2495, 2020
2032020
Leukocytoreduction for acute leukemia
P Porcu, S Farag, G Marcucci, SR Cataland, MS Kennedy, M Bissell
Therapeutic apheresis 6 (1), 15-23, 2002
2002002
Venous thromboembolic disease
MB Streiff, PL Bockenstedt, SR Cataland, C Chesney, C Eby, J Fanikos, ...
Journal of the National Comprehensive Cancer Network 11 (11), 1402-1429, 2013
1962013
Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
M Jin, TC Casper, SR Cataland, MS Kennedy, S Lin, YJ Li, HM Wu
British journal of haematology 141 (5), 651-658, 2008
1612008
Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management
S Sukumar, B Lämmle, SR Cataland
Journal of clinical medicine 10 (3), 536, 2021
1572021
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura
XL Zheng, HM Wu, D Shang, E Falls, CG Skipwith, SR Cataland, ...
Haematologica 95 (9), 1555, 2010
1502010
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naďve to complement inhibitor treatment
E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, ...
Kidney international 97 (6), 1287-1296, 2020
1402020
International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related …
M Scully, S Cataland, P Coppo, J de la Rubia, KD Friedman, ...
J Thromb Haemost 15 (2), 312-322, 2017
1362017
How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome
SR Cataland, HM Wu
Blood, The Journal of the American Society of Hematology 123 (16), 2478-2484, 2014
1342014
Myeloid growth factors
J Crawford, J Armitage, L Balducci, PS Becker, DW Blayney, SR Cataland, ...
Journal of the National Comprehensive Cancer Network 11 (10), 1266-1290, 2013
1322013
Redefining outcomes in immune TTP: an international working group consensus report
A Cuker, SR Cataland, P Coppo, J de La Rubia, KD Friedman, JN George, ...
Blood, The Journal of the American Society of Hematology 137 (14), 1855-1861, 2021
1262021
Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP
SR Cataland, VM Holers, S Geyer, S Yang, HM Wu
Blood, The Journal of the American Society of Hematology 123 (24), 3733-3738, 2014
1252014
Venous thromboembolic disease: Clinical practice guidelines in Oncology™
LD Wagman, MF Baird, CL Bennett, PL Bockenstedt, SR Cataland, ...
JNCCN Journal of the National Comprehensive Cancer Network 4 (9), 838-869, 2006
125*2006
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
F Peyvandi, M Scully, JAK Hovinga, P Knöbl, S Cataland, K De Beuf, ...
Journal of Thrombosis and Haemostasis 15 (7), 1448-1452, 2017
1122017
The system can't perform the operation now. Try again later.
Articles 1–20